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Context: Thyroperoxidase antibody (TPOAb) positivity is a major risk factor for gestational 
thyroid dysfunction. During the first 18-20 weeks of pregnancy, high concentrations of human 
chorionic gonadotropin (hCG) stimulate the thyroid to ensure adequate thyroid hormone 
availability for the developing fetus. However, TPOAb positive women have an impaired 
thyroidal response to hCG stimulation. 
Objective: To study the association of maternal TPOAb positivity during pregnancy with child 
IQ. 
Design, Setting, Participants: This study was embedded in two prospective birth cohorts: 
Generation R (Rotterdam, the Netherlands) and the Avon Longitudinal Study of Parents and 
Children (ALSPAC; United Kingdom). Mother-child pairs with available early pregnancy  
TPOAb data (≤18 weeks of gestation) and offspring IQ were included (N=3637, Generation R 
and N=2396, ALSPAC).  
Intervention: None. 
Main Outcome Measures: Child IQ at 5 to 10 years of age. 
Results: In Generation R, TPOAb positivity was associated with a 2.0 ±0.9 point lower mean 
child IQ (P=0.03). Sensitivity analyses showed negative effect estimates already from TPOAb 
concentrations considerably lower than currently used manufacturer cut-offs. In ALSPAC, 
neither TPOAb positivity nor TPOAb concentrations below manufacturer cut-offs were 
associated with child IQ (TPOAb positivity: 0.7 ±1.0, P=0.45). Adjustment for maternal TSH or 
FT4 concentrations or urinary iodine/creatinine ratio did not change the results. 
Conclusion: TPOAb positivity during pregnancy was associated with lower child IQ in 
Generation R but not in ALSPAC. Further studies are needed to elucidate if differences between 
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the study populations, such as maternal iodine status, could be the underlying cause for these 
differences. 
We investigated the association of early pregnancy TPO antibody positivity with child IQ and demonstrate 
that TPO antibody positive women have children with lower IQ in one of the two studied cohorts. 
Introduction 
Thyroperoxidase antibody (TPOAb) positivity occurs in about 2-17% of all pregnant women 
worldwide and its prevalence differs according to maternal iodine intake and ethnicity (1). 
TPOAb positivity reflects thyroid autoimmunity, which typically results in higher serum thyroid 
stimulating hormone (TSH) concentrations, lower serum free thyroxine (FT4) concentrations and 
ultimately hypothyroidism (2,3). Human chorionic gonadotropin (hCG) is a pregnancy-specific 
hormone that exerts thyrotropic activity via its affinity for the TSH receptor (4). During 
pregnancy, high hCG concentrations are associated with an up to 50% increase in FT4 
concentrations (5). This increase in thyroid hormone availability ensures sufficient thyroxine 
availability for placental thyroxine transfer to the developing fetus (6). Although we recently 
showed that TPOAb positivity severely impairs the thyroidal response to hCG stimulation, it 
remains unknown whether this could affect early fetal development (7). 
The fetal thyroid gland is not functionally mature until the 18th to 20th week of pregnancy; 
therefore, fetal thyroid hormone availability largely depends on the placental transfer of maternal 
thyroid hormones during early development (6,8). In humans, neurogenesis starts from 
approximately the 5th week of pregnancy and thyroid hormone receptors are detected in the fetal 
brain from the 8th week of pregnancy (8). Various critical processes of fetal brain development 
that reach peak activity before the 18th to 20th week of pregnancy are regulated by thyroid 
hormone (9). Interestingly the specific  period that early fetal brain development is dependent on 
maternal thyroid hormones overlaps with peaking of hCG concentrations, facilitating a 
concomitant increase in maternal thyroid hormone concentrations (roughly 6-15  weeks of 
pregnancy) (5,10). 
The current guidelines of the American Thyroid Association (ATA) state that for TPOAb 
positive women, levothyroxine treatment can be considered when TSH concentrations are above 
2.5 mU/l (1). This recommendation is predominantly based on studies showing that TPOAb 
positivity is associated with a higher risk of miscarriage and premature delivery (1,11-14). Mild 
maternal thyroid dysfunction, particularly hypothyroxinemia has been associated with 
suboptimal child neurodevelopmental outcomes, such as attention-deficit/hyperactivity disorder 
symptoms, lower IQ, autism and schizophrenia (15-18); however, studies on the association of 
maternal TPOAb positivity with child neurodevelopment remain sparse. While some studies 
have shown that maternal TPOAb positivity is associated with lower child IQ or other adverse 
neurodevelopmental outcomes (19-22), the majority of these studies were either retrospective, 
had a small sample size, were unable to adjust for potential confounders and/or did not 
specifically investigate the combination of TPOAb positivity and an elevated TSH concentration.  
Considering that an attenuated thyroidal response to hCG stimulation in TPOAb positive 
women likely leads to a relative form of thyroid hormone shortage during early pregnancy, 
during which fetal brain development depends on maternal thyroid hormone, we hypothesized 
that TPOAb positivity is associated with lower child IQ. To address this, we examined the 
association of maternal TPOAb positivity during pregnancy with child IQ in two large, 
prospective, population-based cohorts. 
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Methods 
This study was embedded in two prospective birth cohorts: Generation R (Rotterdam, the 
Netherlands) and the Avon Longitudinal Study of Parents and Children (ALSPAC, United 
Kingdom).  
Study design and participants 
In Generation R, 7,069 women with a delivery date between April 2002 and January 2006 were 
enrolled during early pregnancy (≤18 weeks) in hospitals and midwife practices in Rotterdam 
(23). Blood samples were drawn in 6,398 of these women and 5,793 had enough material for 
measurement of TPOAbs. When the children reached 5 years of age, all enrolled mothers and 
children were invited to visit the research center at the Erasmus MC Sophia Children’s Hospital 
in Rotterdam, where 3,753 (64%) children underwent IQ assessments. The general study design, 
all research aims, and the specific measurements in the Generation R Study have been approved 
by the Medical Ethical Committee of the Erasmus Medical Center, Rotterdam, Netherlands. 
Written informed consent was obtained from all participants and/or the children’s parents or 
guardians. 
In ALSPAC, eligible women were those living in the former Avon area in southwest 
England, United Kingdom, with an expected delivery date between April, 1991, and December, 
1992. In total, blood samples were available in 7,501 pregnant women, of which 4,947 were 
enrolled during early pregnancy (≤18 weeks) (24) with 4,916 women having TPOAb 
measurements. Subsequently, all participants were invited to attend a research clinic where 
trained psychologists measured the IQ of 2,552 children. The study website contains details of all 
the data that are available through a fully searchable database 
www.bris.ac.uk/alspac/researchers/data-access/data-dictionary/. Ethical approval for the study 
was obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics 
Committees. 
The exclusion criteria for both cohorts were twin pregnancies, women with pre-existing 
thyroid disease or fertility treatment and outliers of child IQ (defined as ±2.5*median absolute 
deviation ). 
Laboratory Measurements 
In Generation R, maternal blood samples were stored at -80° C. TPOAbs were measured using 
the Phadia 250 immunoassay (Phadia AB, Uppsala, Sweden) and considered positive when the 
serum concentrations were >60 IU/ml. FT4 and TSH were measured using chemiluminescence 
assays (Vitros ECI Immunodiagnostic System Ortho Clinical Diagnostics, Rochester, NY). The 
intra- and interassay coefficients of variation were <4.1% for TSH at a range of 3.97–22.7 mU/L 
and <5.4% for FT4 at a range of 14.3–25.0 pmol/L. Details of the urinary iodine and creatinine 
measurement are reported elsewhere (25).  
In ALSPAC, TPOAb, FT4 and TSH were measured in stored serum samples using an Abbott 
Architect i2000. Inter- and intra-assay coefficients of variation were less than 5% for all analytes. 
TPOAbs were considered positive when the serum concentrations were ≥6 IU/ml. Details on 
urinary iodine and creatinine measurements on a very limited subset are reported elsewhere (26). 
Outcomes 
In Generation R, non-verbal child IQ was evaluated using two subtests of a Dutch non-verbal 
intelligence test, the Snijders-Oomen Niet-Verbale Intelligentie Test when the children were 5 to 
8 years of age. The test generally evaluates a range of intelligence functions without relying on 
language skills and is therefore suitable for assessing the cognitive abilities of ethnic minorities’ 
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children and children with verbal communication problems (27). The two subtests were mosaics 
(evaluating spatial visualization abilities) and categories (evaluating abstract reasoning abilities) 
and the correlation between subtests with complete test were: r=0.86. Raw test scores were 
converted into non-verbal IQ scores using normal values tailored to exact age. Research staff 
who did the IQ tests were unaware of any other mother-child measurements and outcomes.  
In ALSPAC, child IQ was measured in a research clinic using a well-validated age-adjusted 
shortened form of the Wechsler Intelligence Scale for Children (WISC) which provides a well-
standardized assessment of performance and verbal intelligence when children were 7 to 10 
years of age (26,28). WISC assessments were administered by trained psychologists. To compare 
analyses to Generation R, the performance component of child IQ was used as the primary 
outcome, supplementary analyses were also performed for the verbal component. 
Statistical analysis 
We used multivariable linear regression analyses to investigate the association of maternal 
TPOAb positivity with child IQ. We have recently shown that thyroid function and the response 
to hCG stimulation is already lower from concentrations below currently used TPOAb positivity 
cut-offs as provided by assay manufacturers (29). Therefore, we also performed sensitivity 
analyses to evaluate the effects of cut-offs below the currently used manufacturer-based cut-offs. 
TPOAbs were categorized at 20, 30, 40, 50 and 60 IU/ml in Generation R (corresponding to 
population-based percentiles: 90.6, 92.2, 93, 93.6 and 94.1, respectively). Considering that the 
manufacturer’s cut-off of TPOAb in the ALSPAC population (6 IU/ml) already stood at the 87.2 
percentile, to enable comparison between cohorts, population-based cut-offs equivalent to the 
cut-offs in Generation R were defined in ALSPAC (14.2, 29.6, 41.4, 54.8 and 63.1 IU/ml, 
respectively). The effect estimates for these cut-offs were compared with TPOAb <10 IU/ml 
(population-based percentile of 83) in Generation R and the corresponding percentile (<4.16 
IU/ml) in ALSPAC. The severely skewed distribution of (log-transformed) TPOAb 
concentrations did not allow for reliable analyses using TPOAb concentrations as a continuous 
exposure.  
Based on the current ATA guidelines (1), we additionally investigated the group of TPOAb 
positive women with a TSH concentration >2.5 mU/L (N=118 (3.4 %) and N=52 (2.46 %), in 
Generation R and ALSPAC, respectively. Because maternal iodine status is a well-known 
determinant of both thyroid autoimmunity and child IQ (26,30), in a subset of mothers with 
available early pregnancy iodine data (N=1330 in Generation R and N=1065 in ALSPAC) we 
investigated the possible effects of maternal iodine status on the association of TPOAbs with 
child IQ by: 1) studying the association of TPOAbs with maternal urinary iodine/creatinine ratio 
(UICr) using a linear regression model; 2) additionally adjusting all analyses for maternal UICr; 
and 3) stratified analyses in both cohorts according to a UICr below and above 150 µg/g. 
Furthermore, we also investigated if the association of maternal TPOAbs with child IQ would be 
(partially) mediated via changes in maternal thyroid function by additionally adjusting all models 
for maternal FT4 and TSH. 
All analyses were adjusted for maternal age, body mass index and gestational age at the time 
of blood sampling, parity, smoking status, education level, ethnicity,  child sex and birth weight. 
We used multiple imputation by chained equations to deal with missing data of covariates (31). 
The maximum percentage of missing data was 10.3% in Generation R and 3.7% for ALSPAC. 
The number of imputations were based on the percentage of missing data using at least 1 
imputation per percent of incomplete cases . All statistical analyses were performed using SPSS 
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version 21.0 for Windows or R statistical software version 3.3.2 (packages mice and rms; 
https://www.r-project.org/).  
Results 
After exclusions, the final study population included 6,033 mother-child pairs (Generation R: 
N=3,564; ALSPAC: N=2,362, Figure 1). Mother-child characteristics of the study population are 
shown in Table 1. In Generation R, the prevalence of TPOAb positivity was 5.9%, mean 
gestational age at blood sampling was 13.4 (SD 1.9) weeks and the study population was mainly 
of Dutch ethnicity (57.3%). In ALSPAC, the prevalence of TPOAb positivity was 12.8%, mean 
gestational age at blood sampling was 10.9 (SD 3.1) weeks and the study population was mainly 
of Caucasian ethnicity (98.5%). In both cohorts, there was no difference in maternal TPOAb 
positivity or thyroid function between mother-child pairs with or without IQ data available 
(Supplemental Tables 1 and 2). 
In Generation R, maternal TPOAb positivity was associated with lower mean child IQ (-2.0 
±0.9 points, P=0.03; Table 2). Subsequent sensitivity analyses showed that mean child IQ was 
already  lower at TPOAb cut-offs below the currently used manufacturer-based cut-off for 
TPOAb positivity (Table 2). In ALSPAC, using cut-offs equivalent to Generation R, neither 
TPOAb positivity nor TPOAb cut-offs below the manufacturer-based cut-off were associated 
with child IQ (TPOAb positivity: 0.7 ±0.9 points; P=0.45; Table 2). The combination of TPOAb 
positivity with a TSH above 2.5 mU/l was not associated with child IQ in Generation R (P for 
interaction=0.52) while this combination was associated with a higher mean child IQ in 
ALSPAC (P for interaction=0.09; Supplemental Table 3). All results remained essentially 
unchanged after adjusting for maternal FT4 concentrations (Table 2), UICr (Supplemental Table 
4), maternal TSH concentrations (data not shown) or hCG concentrations (Generation R only; 
data not shown). In Generation R, the association of TPOAbs with child IQ did not differ 
according to maternal ethnicity. 
The median maternal UICr differed considerably between Generation R and ALSPAC 
(median (IQR): 295 (199-425) vs. 117 (80-190), P<0.001). In ALSPAC, but not in Generation R, 
higher TPOAb concentrations or TPOAb positivity were associated with higher maternal UICr, 
although these analyses did not reach statistical significance in the smaller subgroups 
(Supplemental Table 5). Sensitivity analyses suggested that the association of maternal TPOAb 
positivity with child IQ may differ according to maternal iodine status, although we lacked 
adequate statistical power for this analysis (Supplemental Table 6). There was no association of 
UICr with thyroid function in the two cohorts (Data not shown). 
Discussion 
In this study, we investigated the association of TPOAb positivity during early pregnancy with 
child IQ in two large prospective population-based cohorts. We show that TPOAb positivity as 
defined by currently used manufacturer-based cut-offs was associated with lower mean child IQ 
in the Netherlands (Generation R) but not in the United Kingdom (ALSPAC). Furthermore, the 
association of TPOAbs with lower child IQ in the Netherlands was already present from TPOAb 
cut-offs below the currently used manufacturer-based cut-offs. Additional adjustment for 
maternal FT4 or TSH or UICr did not change the results.  
There is an overlap in the time period of fetal brain development’s peak activity, fetal 
dependency on placental transfer of maternal thyroid hormones and hCG mediated increase in 
maternal FT4 concentrations (4,8,9). However, TPOAb positive women have an impaired 
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response to the thyroidal stimulation by hCG and low maternal thyroid hormone availability is 
associated with lower child IQ in some but not all studies (32-35). In the current study, TPOAb 
positivity was associated with lower child IQ in Generation R, which might have been due to a 
lack of hCG mediated increase in FT4 concentrations during early pregnancy (29). Alternatively, 
TPOAb positivity could be associated with lower child IQ because TPOAb positivity reflects a 
higher general susceptibility to autoimmunity. Maternal autoimmunity or a familial history of 
autoimmune disorders has been associated with a higher risk of child autism (36,37). A third 
potential explanation would be a direct effect of TPOAbs on the brain. TPOAbs can cross the 
placenta and have been detected in the cerebrospinal fluid of patients with Hashimoto’s 
encephalitis (38,39). In addition, since newborn and childhood TSH or FT4 do not differ 
between TPOAb-positive and TPOAb-negative mothers (40) and newborn thyroid function is not 
associated with neurocognitive outcomes (41,42) a pathway via changes in child thyroid function 
is highly unlikely.  
However, although TPOAb positivity was associated with a lower child IQ in Generation R, 
there was no association in ALSPAC, with point estimates even suggesting a positive association 
of TPOAb positivity with child IQ. There might be several reasons for the discrepancy between 
the two cohorts. First, there is a large difference in iodine status of pregnant women between the 
Netherlands (more than sufficient) and United Kingdom (mildly deficient), as was also reflected 
by the UICr analyses in the current study. Both low and high iodine intake are risk factors for 
low maternal thyroid hormone availability and both are associated with an increased risk of 
thyroid autoimmunity (30,43). Previous studies have shown that in the iodine sufficient 
population of Generation R, a single low maternal UICr measurement is not associated with 
child IQ, whereas a low UICr measurement in the iodine deficient ALSPAC cohort is associated 
with lower child IQ (26,44). Stratified analysis suggested that in Generation R, the association of 
TPOAb positivity with lower child IQ was driven predominantly by women with a UICr  ≥150 
µg/g. This would indicate that in Generation R, low iodine status is not the underlying 
mechanism. In ALSPAC, there was a suggestive association of higher TPOAb concentrations or 
TPOAb positivity with a higher maternal UICr, although the small size of the subset with 
available data did not provide adequate statistical power. Similarly, a higher iodine availability 
could underlie the higher mean IQ in the small subset of TPOAb positive women with a TSH 
above 2.5 mU/L. However, neither in Generation R nor in ALSPAC we could adequately asses 
iodine status in this small subset due to a lack of data availability (data not shown) and in 
addition, we were only powered to detect a roughly 3.6 point IQ difference in the subset of 
TPOAb positive women with a TSH above 2.5 mU/L in Generation R. Taken together, this 
might suggest that the difference between Generation R and ALSPAC could be due to the 
differences in iodine status between the two cohorts. Unfortunately, data on UICr were only 
available in a small subset for both studies, precluding adequate analyses to investigate the role 
of UICr as an underlying cause for the differences between the two cohorts. In line with our 
hypothesis, TPOAb positivity has been associated with impaired child cognition, autism and 
behavioral problems in other studies from iodine sufficient populations (21,22,45) whereas a 
Scottish study with 40% of women being iodine deficient did not find an association with 
neurodevelopmental outcomes (20).  
Second, while serum samples in Generation R were collected between 2002 and 2005, and 
TPOAbs were measured in 2006, ALSPAC samples were collected between 1991 and 1992 and 
measured in 2016. A study from Finland shows that in stored serum samples, there is a strong 
positive association of storage time with TPOAb concentrations, with storage time explaining 
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19.7% of the total variation in TPOAb concentrations (46). This indicates that TPOAb 
concentrations in ALSPAC are much more likely to be subject to measurement error than those 
in Generation R. Although it is unknown whether the extent of the increase in TPOAb 
concentration by storage time is differential on factors that may affect IQ, the difference in 
storage time may hamper the comparisons between Generation R and ALSPAC in the current 
study. 
The current ATA guidelines recommend that treatment can be considered in TPOAb positive 
women if the TSH concentration is >2.5 mU/l (1). In the current study, the association of TPOAb 
positivity with lower child IQ in Generation R did not differ according to a TSH below or above 
2.5 mU/l. Given that the guideline recommendations are predominantly based on studies 
focusing on adverse obstetric outcomes, the lack of effects in the current study cannot be 
considered as an argument against current recommendations. Nonetheless, further studies are 
required to investigate from which TSH threshold the risk of adverse outcomes in TPOAb 
positive women starts to increase.  
In the current study, we also showed that TPOAb cut-offs below the currently used 
manufacturer-based cut-offs for TPOAb positivity were associated with a lower child IQ. This is 
in line with a previous study from our group, showing that TPOAb concentrations already below 
currently used manufacturer cut-offs are associated with a higher TSH and a higher risk of 
premature delivery (29). Taken together, this suggests that the clinically relevant cut-off for 
TPOAb positivity may differ from the currently used manufacturer-based cut-offs and that future 
studies should focus on identifying the optimal threshold for TPOAb positivity for different 
pregnancy and offspring outcomes. 
To the best of our knowledge, this is the first study to assess the association of early 
pregnancy TPOAb positivity with child IQ in two large prospective, population-based cohorts. 
We were able to study this association in two study populations with a different population 
iodine status with detailed data that allowed us to adjust the models for important confounders 
and run additional sensitivity analyses. 
A potential limitation of this study is that data on maternal iodine excretion were not 
available for all mothers which left us with inadequate statistical power for sensitivity analysis 
investigating the potential role of iodine intake. Further studies are therefore needed to 
investigate the role of maternal thyroid autoimmunity in relation to iodine status with regard to 
child cognitive development. In addition, the number of TPOAb positive women with a TSH 
>2.5 mU/l was small, hampering an adequately powered analysis for this subgroup. Finally, the 
comparisons of the two cohorts was limited mainly because of differences in tests used to assess 
IQ. In ALSPAC, a verbal IQ test was performed which differs from non-verbal IQ as tested in 
Generation R, the latter of which can overcome potential interference by language development 
delays. Nonetheless, in a recent study comparing three cohorts using three different IQ test, 
similar results were obtained for the effects of low thyroid function (47). 
In conclusion, we demonstrate that TPOAb positivity during early pregnancy is associated 
with lower child IQ in a Dutch, iodine sufficient population, but not in a mildly iodine deficient 
population from the United Kingdom. In addition, TPOAb cut-offs below the current 
manufacturer-based cut-offs were associated with lower mean child IQ in the Netherlands. 
Further studies are needed to investigate the association of TPOAbs with child 
neurodevelopment outcomes in different populations, and evaluate whether factors that affect 
thyroid autoimmunity, such as iodine status, might possibly modify this association.   
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Figure 1. Flowchart of the study population.  
Table 1. Characteristics of mother–child pairs from the Generation R Study and Avon 
Longitudinal Study of Parents And Children (ALSPAC). 
 Generation R ALSPAC 
Maternal characteristics N=3564 N=2362 
Thyroid peroxidase antibodies (IU/mL) 3.2 (0.0-7.1) 1.9 (1.3-3.1) 
Thyroid peroxidase antibodies positivity, n(%) 214 (5.9) 286 (12.8) 
Free thyroxine (pmol/L) 15.2 (3.6) 16.5 (2.5) 
Thyroid-stimulating hormone (mU/L) 1.37 (0.85-2.05) 0.99 (0.64-1.44) 
Gestational age (weeks) 13.4 (1.8) 10.9 (3.1) 
Age 30.3 (4.8) 28.2 (4.5) 
BMI 24.4 (4.2) 22.8 (3.5) 
Education level, %   
None or primary only 8.4 13.1 
Secondary phase 1 (3–4 years) 12.5 9.0 
Secondary phase 2 (4–5 years) 31.6 35.6 
Higher phase 1 (6–8 years) 22.3 26.6 
Higher phase 2 (>8 years) 25.2 15.7 
Parity, %   
0 59.0 47.2 
1 29.1 34.2 
≥2 11.7 18.6 
Smoking, %   
Non-smokers 73.4 81.0 
Previous smokers 9.65 4.8 
Current smokers 16.9 14.2 
Ethnic origin, %   
Dutch 57.3 - 
Moroccan 5.14 - 
Turkish 7.34 - 
Surinamese 7.80 - 
Cape Verdian 4.09 - 
Asian 4.26 - 
Other European, North American, or Australian 8.71 - 
Other ethnicities 5.30 - 
Caucasian - 98.5 
Other ethnicities - 1.5 
Child characteristics   
Child IQ 101.41 (15.1) 99.5 (16.9) 
Birthweight (g) 3434 (548) 3460 (523) 
Sex (female), % 50.8 49.8 
Data are median (inter-quartile range), mean (SD) or percentage. 
Table 2.  Differences in mean child IQ scores according to thyroid peroxidase antibodies in 
Generation R and ALSPAC. 
Generation R     
TPOAb (IU/mL) β±SE P value β±SE (+FT4)a P value 
Positivity b -2.10±0.92 0.02 -2.00±0.92 0.03 
vs. <10 c     
>20 -1.30±0.75 0.08 -1.14±0.75 0.13 
>30 -1.72±0.81 0.03 -1.55±0.82 0.05 
>40 -1.80±0.85 0.03 -1.69±0.85 0.04 
>50 -2.17±0.89 0.01 -2.06±0.89 0.02 
ALSPAC     
TPOAb (IU/mL) β±SE P value β±SE (+FT4)a P value 
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Positivity b 0.74±0.97 0.43 0.72±0.97 0.45 
vs. <4.16 c     
>14.2 1.73±1.12 0.12 1.68±1.12 0.13 
>29.6 1.79±1.21 0.13 1.73±1.21 0.15 
>41.4 1.80±1.27 0.15 1.74±1.28 0.17 
>54.8 2.29±1.32 0.08 2.22±1.33 0.09 
>63.1 2.11±1.38 0.12 2.03±1.38 0.14 
TPOAb, Thyroid Peroxidase Antibodies; SE, standard error; FT4, maternal free thyroxine. 
Beta±SE are calculated using a linear regression model, adjusted for gestational age at the time of sampling, 
maternal age, maternal body mass index, education, ethnicity, smoking status, parity, birth weight and child sex. 
a Additionally adjusted with FT4. 
b Defined as TPOAb>60 (IU/mL) or TPOAb>6 (IU/mL) in Generation R and ALSPAC, respectively. 
c Those with TPOAbs  values between 10 IU/mL or 4.16 IU/mL and each cut-off were excluded from the analysis. 

